ROIV

Roivant Sciences Ltd

36.49

Oct 23 • 3:59 PM ET -0.96 (-2.56%)

36.69

Aftermarket • 7:30 PM ET +0.20 (0.54%)

Healthcare Biotechnology United Kingdom Large NASD

Peers: ARGX INCY BBIO ALNY ABVX INSM REGN MRNA VRTX IONS

| Held by: IJH VTI VB XMMO VBK VXF MDY IBB XBI SPMD

Index	-
Market Cap	26.36B
Enterprise Value	23.31B
Income	-266.25M
Sales	7.53M
Book/sh	5.86
Cash/sh	5.32
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	721
IPO	Dec 08, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	3500.34
P/B	6.23
P/C	6.85
P/FCF	-
EV/EBITDA	-
EV/Sales	3095.49
Quick Ratio	16.72
Current Ratio	16.72
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	Yes / Yes

EPS (ttm)	-0.44
EPS next Y	-1.31
EPS next Q	-0.37
EPS this Y	-154.96%
EPS next Y	4.98%
EPS next 5Y	5.61%
EPS past 3/5Y	32.67% 34.68%
Sales past 3/5Y	-48.73% -19.07%
EPS Y/Y TTM	45.61%
Sales Y/Y TTM	-67.58%
EPS Q/Q	19.77%
Sales Q/Q	-33.55%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-11.72% -29.89%

Insider Own	27.42%
Insider Trans	-3.31%
Inst Own	76.34%
Inst Trans	3.89%
ROA	-5.15%
ROE	-6.21%
ROIC	-6.15%
Gross Margin	43.37%
Oper. Margin	-18146.12%
Profit Margin	-3534.96%
SMA20	3.30%
SMA50	-0.42%
SMA200	17.15%
Trades

Shs Outstand	722.67M
Shs Float	524.29M
Short Float	7.50%
Short Ratio	5.31
Short Interest	39.30M
52W High	42.50 -14.14%
52W Low	17.89 103.97%
Volatility	4.54% 3.63%
ATR (14)	1.43
RSI (14)	53.35
Beta	1.23
Rel Volume	1.11
Avg Volume	7.41M
Volume	8,217,197

Perf Week	8.83%
Perf Month	1.00%
Perf Quarter	5.10%
Perf Half Y	33.13%
Perf YTD	68.16%
Perf Year	101.38%
Perf 3Y	324.55%
Perf 5Y	436.62%
Perf 10Y	-
Recom	1.40
Target Price	48.91
Prev Close	37.45
Price	36.49
Change %	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-12-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-17-26	Initiated	Stifel	Buy	$51
Mar-20-26	Initiated	Bernstein	Outperform	$35
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Oct-21-26 09:09AM	Roivant Sciences stock surges on positive uveitis trial data (Investing.com) +5.38%
07:00AM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026 (GlobeNewswire)
07:00AM	Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU) (GlobeNewswire)
Oct-08-26 01:33PM	IMVT, ROIV Stocks Slide As Argenx Sjögrens Trial Failure Hits Drug Class (Stocktwits)
Sep-23-26 08:12AM	Roivant's Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss (InvestorsHub)
07:00AM	Loading…
07:00AM	Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus (GlobeNewswire)
Sep-10-26 07:55AM	Podcast: key readouts from ESC and ERS (Pharmaceutical Technology)
Sep-08-26 11:00PM	Why Did DELL, ROIV, SHEL Stocks Surge To 52-Week Highs Today? (Stocktwits) +18.75%
01:53PM	These 2 Biotech Stocks Hit Record Highs Today Whats Driving The Rallies? (Stocktwits)
12:36PM	Roivant Sciences Stock Soars as Lung Disease Drug Hits Goals (Barrons.com)
11:18AM	Why These Two Hot Biotech Stocks Just Surged To Record Highs (Investor's Business Daily)
07:51AM	Roivants Experimental Lung Disease Drug Hits Key Phase 2 Goal ROIV Stock Tracks All-Time High (Stocktwits)
06:55AM	Roivant Sciences Shares Rise After Phase 2 Mosliciguat Results (InvestorsHub)
06:00AM	Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study (GlobeNewswire)
Sep-06-26 01:00AM	Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call (GlobeNewswire)
03:29PM	Loading…
Aug-27-26 03:29PM	Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. (GlobeNewswire)
03:28PM	Priovant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. (GlobeNewswire)
Aug-26-26 11:11AM	JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis (GlobeNewswire)
Aug-06-26 03:02PM	Roivant Sciences Ltd (ROIV) (Q1 2026) Earnings Call Highlights: Strategic Advances and Strong ... (GuruFocus.com)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update (GlobeNewswire)
07:00AM	Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Jul-23-26 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 (GlobeNewswire)
Jul-07-26 02:28PM	ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week (Stocktwits)
May-20-26 03:00PM	Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ... (GuruFocus.com) +14.89%
01:20PM	Can a New Arthritis Drug Make Immunovant the Next Biotech Star? (Barrons.com)
11:38AM	2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug (Barrons.com)
08:45AM	Roivant Shares Climb on Earnings Beat Despite Revenue Shortfall (ROIV) (InvestorsHub)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update (GlobeNewswire)
May-11-26 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 (GlobeNewswire)
Apr-02-26 05:00AM	Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) (GlobeNewswire)
05:00AM	Loading…
05:00AM	Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) (GlobeNewswire)
Mar-28-26 03:00PM	New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis (GlobeNewswire)
Mar-04-26 04:04PM	Moderna Stock Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily) +6.00%
02:35PM	Moderna Settles a Covid Vaccine Patent Lawsuit. What It Means for the Stock. (Barrons.com)
09:55AM	MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS (Zacks)
09:15AM	Stocks to Watch Wednesday: Coinbase, CrowdStrike, Gitlab, Moderna (The Wall Street Journal)
09:01AM	Moderna Pops After Inking $950 Million Covid Vaccine Settlement (Investor's Business Daily)
08:40AM	Moderna and Ross Stores Lead Stock Gainers on Wednesday (24/7 Wall St.)
08:14AM	Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars (Benzinga)
Mar-03-26 04:15PM	Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna (GlobeNewswire)
07:00AM	Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis (GlobeNewswire)
Feb-14-26 01:29AM	Citi Raises Roivant Sciences (ROIV) PT to $35 Following Positive Phase 2 Brepocitinib Data (Insider Monkey)
Feb-10-26 06:41AM	TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) - Here's Why (Insider Monkey)
Feb-08-26 08:39AM	Lumentum, Woodward, And Teradyne Are Among the Top 10 Large-Cap Gainers Last Week (Feb. 2-Feb. 6): Are the Others in Your Portfolio? (Benzinga)
Feb-07-26 06:38AM	Roivant Sciences (ROIV) Soars 19.4% as Pipeline Drugs Progress (Insider Monkey)
Feb-06-26 02:05PM	Roivant Stock Soars On Experimental Skin Drug Delivering 100% Response - Why It Matters (Benzinga) +22.14%
02:00PM	Roivant Sciences Ltd (ROIV) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... (GuruFocus.com)
01:25PM	Tech Bounces As Software Sell-Off Eases, Dow Jones Hits Records: What's Moving Markets Friday? (Benzinga)
10:10AM	Roivant Sciences Q3 Earnings Call Highlights (MarketBeat)
10:03AM	Roivant Sciences Catapults On A 'Dream Scenario' For Its Blockbuster Hopeful (Investor's Business Daily)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025 (GlobeNewswire)
07:00AM	Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) (GlobeNewswire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-23-26 04:15PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire)
Jan-20-26 10:31AM	Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report (Benzinga)
Jan-02-26 10:50AM	Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline (Insider Monkey)
Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venker Eric	President & Immunovant CEO	Oct 20 '26	Sale	35.11	200,000	7,022,668	1,399,154	Oct 22 06:44 PM
Venker Eric	Officer	Oct 20 '26	Proposed Sale	35.12	200,000	7,023,513		Oct 20 04:44 PM
Epperly Melissa B,	Director	Oct 01 '26	Option Exercise	4.46	17,750	79,165	32,704	Oct 05 06:05 PM
Epperly Melissa B,	Director	Oct 01 '26	Sale	36.10	17,750	640,861	14,954	Oct 05 06:05 PM
Venker Eric	President & Immunovant CEO	Sep 30 '26	Option Exercise	3.85	200,000	770,000	1,799,154	Oct 02 05:37 PM
Venker Eric	President & Immunovant CEO	Sep 30 '26	Sale	36.62	200,000	7,324,000	1,599,154	Oct 02 05:37 PM
Venker Eric	Officer	Sep 30 '26	Proposed Sale	36.62	200,000	7,323,556		Sep 30 04:21 PM
Epperly Melissa B,	Director	Sep 15 '26	Sale	39.74	4,938	196,230	9,900	Sep 17 06:43 PM
Fitzgerald Meghan	Director	Sep 15 '26	Sale	39.74	5,112	203,152	36,108	Sep 17 06:42 PM
MELISSA EPPERLY	Director	Sep 15 '26	Proposed Sale	41.02	22,688	930,662		Sep 15 04:40 PM
MEGHAN FITZGERALD	Officer	Sep 15 '26	Proposed Sale	41.02	5,112	209,694		Sep 15 04:32 PM
Fitzgerald Meghan	Director	Sep 08 '26	Option Exercise	8.80	20,000	176,000	62,963	Sep 10 09:00 PM
Fitzgerald Meghan	Director	Sep 08 '26	Sale	39.90	20,000	798,000	42,963	Sep 10 09:00 PM
MEGHAN FITZGERALD	Director	Sep 08 '26	Proposed Sale	34.93	20,000	698,600		Sep 08 04:27 PM
Venker Eric	President & Immunovant CEO	Aug 28 '26	Option Exercise	3.85	200,000	770,000	1,799,154	Sep 01 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 28 '26	Sale	35.77	200,000	7,153,393	1,599,154	Sep 01 09:00 PM
Venker Eric	Officer	Aug 28 '26	Proposed Sale	35.74	200,000	7,147,088		Aug 28 04:33 PM
Sukhatme Mayukh	President & CIO	Aug 19 '26	Option Exercise	3.85	172,899	665,661	18,803,638	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 21 '26	Option Exercise	3.85	144,756	557,311	18,775,495	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 20 '26	Option Exercise	3.85	17,519	67,448	18,648,258	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 19 '26	Sale	37.17	172,899	6,426,656	18,630,739	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 21 '26	Sale	36.48	144,756	5,280,699	18,630,739	Aug 21 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 20 '26	Sale	37.30	17,519	653,459	18,630,739	Aug 21 09:00 PM
MAYUKH SUKHATME	Officer	Aug 21 '26	Proposed Sale	36.48	144,756	5,280,004		Aug 21 04:20 PM
MAYUKH SUKHATME	Officer	Aug 20 '26	Proposed Sale	37.30	17,519	653,408		Aug 20 04:34 PM
MAYUKH SUKHATME	Officer	Aug 19 '26	Proposed Sale	37.17	172,899	6,426,357		Aug 19 04:23 PM
Sukhatme Mayukh	President & CIO	Aug 17 '26	Option Exercise	3.85	284,707	1,096,122	18,915,446	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 14 '26	Option Exercise	3.85	243,177	936,231	18,873,916	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 18 '26	Option Exercise	3.85	136,942	527,227	18,735,880	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 17 '26	Sale	36.25	284,707	10,320,629	18,630,739	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 14 '26	Sale	36.23	243,177	8,810,303	18,630,739	Aug 18 09:00 PM
Sukhatme Mayukh	President & CIO	Aug 18 '26	Sale	36.73	136,942	5,029,470	18,630,739	Aug 18 09:00 PM
MAYUKH SUKHATME	Officer	Aug 18 '26	Proposed Sale	36.73	136,942	5,029,209		Aug 18 04:29 PM
MAYUKH SUKHATME	Officer	Aug 17 '26	Proposed Sale	36.25	284,707	10,320,572		Aug 17 04:40 PM
MAYUKH SUKHATME	Officer	Aug 14 '26	Proposed Sale	36.23	243,177	8,809,768		Aug 14 04:20 PM
Venker Eric	President & Immunovant CEO	Jul 27 '26	Option Exercise	3.85	200,000	770,000	1,813,063	Jul 29 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 27 '26	Sale	34.95	200,000	6,990,000	1,613,063	Jul 29 09:00 PM
Venker Eric	Officer	Jul 27 '26	Proposed Sale	34.95	200,000	6,989,924		Jul 27 04:16 PM
Fitzgerald Meghan	Director	Jun 30 '26	Option Exercise	8.80	10,000	88,000	52,963	Jul 02 07:03 PM
Fitzgerald Meghan	Director	Jun 30 '26	Sale	34.90	10,000	349,000	42,963	Jul 02 07:03 PM
Epperly Melissa B,	Director	Jun 29 '26	Option Exercise	4.46	17,750	79,165	34,224	Jul 01 06:34 PM
Epperly Melissa B,	Director	Jun 29 '26	Sale	34.38	17,750	610,252	16,474	Jul 01 06:34 PM
MANCHESTER KEITH S	Director	Jun 29 '26	Sale	34.55	800,000	27,642,000	13,701,546	Jun 30 08:38 PM
MANCHESTER KEITH S	Director	Jun 26 '26	Sale	34.00	625,783	21,275,309	14,501,546	Jun 30 08:38 PM
MANCHESTER KEITH S	Director	Jun 30 '26	Sale	35.45	200,000	7,090,000	1,748,403	Jun 30 08:38 PM
MANCHESTER KEITH S	Director	Jun 30 '26	Sale	35.28	12,380	436,766	13,689,166	Jun 30 08:38 PM
Gold Daniel Allen	Director	Jun 29 '26	Sale	34.55	800,000	27,642,000	13,701,546	Jun 30 08:30 PM
Gold Daniel Allen	Director	Jun 26 '26	Sale	34.00	625,783	21,275,309	14,501,546	Jun 30 08:30 PM
Gold Daniel Allen	Director	Jun 30 '26	Sale	35.28	12,380	436,766	13,689,166	Jun 30 08:30 PM
QVT Financial LP	Director by Deputization	Jun 29 '26	Sale	34.55	800,000	27,642,000	13,701,546	Jun 30 07:59 PM
QVT Financial LP	Director by Deputization	Jun 26 '26	Sale	34.00	625,783	21,275,309	14,501,546	Jun 30 07:59 PM
QVT Financial LP	Director by Deputization	Jun 30 '26	Sale	35.28	12,380	436,766	13,689,166	Jun 30 07:59 PM
MEGHAN FITZGERALD	Director	Jun 30 '26	Proposed Sale	34.73	10,000	347,300		Jun 30 04:36 PM
KEITH S MANCHESTER	Director	Jun 30 '26	Proposed Sale	35.45	200,000	7,090,280		Jun 30 04:25 PM
MELISSA EPPERLY	Director	Jun 29 '26	Proposed Sale	34.07	17,750	604,742		Jun 29 04:40 PM
Venker Eric	President & Immunovant CEO	Jun 24 '26	Option Exercise	3.85	200,000	770,000	1,813,063	Jun 26 06:13 PM
Venker Eric	President & Immunovant CEO	Jun 24 '26	Sale	33.16	200,000	6,631,268	1,613,063	Jun 26 06:13 PM
MAYUKH SUKHATME	Officer	Jun 26 '26	Proposed Sale	34.08	500,000	17,039,650		Jun 26 04:10 PM
MAYUKH SUKHATME	Officer	Jun 25 '26	Proposed Sale	34.13	500,000	17,066,500		Jun 25 04:33 PM
Venker Eric	Officer	Jun 24 '26	Proposed Sale	33.16	200,000	6,631,659		Jun 24 04:01 PM
Venker Eric	President & Immunovant CEO	May 22 '26	Option Exercise	3.85	200,000	770,000	1,813,063	May 22 06:25 PM
Venker Eric	President & Immunovant CEO	May 22 '26	Sale	30.27	200,000	6,054,000	1,613,063	May 22 06:25 PM
Venker Eric	Officer	May 22 '26	Proposed Sale	30.27	200,000	6,054,731		May 22 04:00 PM
Venker Eric	President & Immunovant CEO	Apr 20 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Apr 22 06:27 PM
Venker Eric	President & Immunovant CEO	Apr 20 '26	Sale	29.59	200,000	5,918,000	1,647,546	Apr 22 06:27 PM
Gline Matthew	CEO	Apr 16 '26	Sale	29.16	289,774	8,449,810	16,736,116	Apr 20 06:27 PM
Venker Eric	Officer	Apr 20 '26	Proposed Sale	29.59	200,000	5,917,135		Apr 20 04:17 PM
Gline Matthew	Officer	Apr 16 '26	Proposed Sale	29.16	289,774	8,449,876		Apr 16 04:33 PM
Humes Jennifer	Chief Accounting Officer	Apr 08 '26	Sale	28.37	13,538	384,073	84,191	Apr 10 06:00 PM
JENNIFER HUMES	Officer	Apr 08 '26	Proposed Sale	28.37	13,538	384,035		Apr 08 04:07 PM
Fitzgerald Meghan	Director	Mar 26 '26	Option Exercise	8.80	70,000	616,000	112,963	Mar 30 09:01 PM
Fitzgerald Meghan	Director	Mar 26 '26	Sale	27.45	70,000	1,921,500	42,963	Mar 30 09:01 PM
MEGHAN FITZGERALD	Director	Mar 26 '26	Proposed Sale	27.45	70,000	1,921,458		Mar 26 04:14 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Option Exercise	3.85	200,000	770,000	1,847,546	Mar 19 06:36 PM
Venker Eric	President & Immunovant CEO	Mar 17 '26	Sale	28.24	200,000	5,648,000	1,647,546	Mar 19 06:36 PM
Epperly Melissa B,	Director	Mar 16 '26	Sale	28.68	41,861	1,200,573	15,804	Mar 18 06:23 PM
Venker Eric	Officer	Mar 17 '26	Proposed Sale	28.24	200,000	5,648,836		Mar 17 04:17 PM
MELISSA B EPPERLY	Director	Mar 16 '26	Proposed Sale	28.68	41,861	1,200,498		Mar 16 04:04 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Option Exercise	3.85	1,400,000	5,390,000	15,136,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Option Exercise	3.85	1,012,610	3,898,548	14,749,157	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Option Exercise	3.85	587,390	2,261,452	14,323,937	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 19 '26	Sale	27.42	1,400,000	38,388,000	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 20 '26	Sale	27.15	1,012,610	27,492,362	13,736,547	Feb 23 08:40 PM
Torti Frank	President and Vant Chair	Feb 23 '26	Sale	27.51	587,390	16,159,099	13,736,547	Feb 23 08:40 PM
FRANK TORTI	Officer	Feb 20 '26	Proposed Sale	27.52	1,600,000	44,032,000		Feb 20 04:29 PM
FRANK TORTI	Officer	Feb 19 '26	Proposed Sale	27.48	1,400,000	38,472,000		Feb 19 04:24 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Option Exercise	3.85	200,000	770,000	1,854,597	Feb 18 05:57 PM
Venker Eric	President & Immunovant CEO	Feb 13 '26	Sale	26.49	200,000	5,298,000	1,654,597	Feb 18 05:57 PM
MANCHESTER KEITH S	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:02 PM
MANCHESTER KEITH S	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:02 PM
Gold Daniel Allen	Director	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 09:00 PM
Gold Daniel Allen	Director	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 09:00 PM
QVT Financial LP	Director by Deputization	Feb 12 '26	Sale	26.75	425,000	11,367,000	15,503,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 11 '26	Sale	26.67	425,000	11,334,750	15,928,113	Feb 13 08:45 PM
QVT Financial LP	Director by Deputization	Feb 13 '26	Sale	26.50	375,784	9,956,768	15,127,329	Feb 13 08:45 PM
Venker Eric	Officer	Feb 13 '26	Proposed Sale	26.49	200,000	5,298,373		Feb 13 04:21 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Option Exercise	12.68	651,558	8,261,755	19,488,105	Feb 11 05:53 PM
Sukhatme Mayukh	President & CIO	Feb 09 '26	Sale	26.47	339,441	8,985,003	19,148,664	Feb 11 05:53 PM

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

CEO & DirectorMr. Matthew Gline

Pharm.D.Dr. Eric Venker M.D.

PresidentDr. Mayukh Sukhatme M.D.

M.D.Dr. Frank M. Torti M.B.A.

Chief Financial OfficerMr. Richard Pulik

Open in Screener

MP

MP Materials Corp

38.30

Oct 23 • 3:59 PM ET -0.26 (-0.67%)

38.49

Aftermarket • 7:59 PM ET +0.19 (0.50%)

Basic Materials Other Industrial Metals & Mining USA Mid NYSE

Peers: USAR ALOY CRML EMAT ALM MTRN NB UUUU REA BHP

| Held by: VTI IJH VB XME REMX VBK VXF MDY DFAS SPMD

Index	-
Market Cap	6.82B
Enterprise Value	6.73B
Income	-60.62M
Sales	416.25M
Book/sh	10.99
Cash/sh	8.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	998
IPO	Jun 22, 2020

P/E	-
Forward P/E	59.44
PEG	-
P/S	16.39
P/B	3.48
P/C	4.69
P/FCF	-
EV/EBITDA	144.51
EV/Sales	16.18
Quick Ratio	8.56
Current Ratio	9.51
Debt/Eq	0.40
LT Debt/Eq	0.40
Option/Short	Yes / Yes

EPS (ttm)	-0.35
EPS next Y	0.64
EPS next Q	-0.02
EPS this Y	81.81%
EPS next Y	1576.07%
EPS next 5Y	-
EPS past 3/5Y	- -13.01%
Sales past 3/5Y	-19.47% 15.45%
EPS Y/Y TTM	44.39%
Sales Y/Y TTM	71.92%
EPS Q/Q	39.60%
Sales Q/Q	119.66%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	0.99% 11.98%

Insider Own	18.63%
Insider Trans	-2.60%
Inst Own	79.15%
Inst Trans	8.17%
ROA	-2.00%
ROE	-3.59%
ROIC	-1.83%
Gross Margin	14.51%
Oper. Margin	-16.71%
Profit Margin	-14.56%
SMA20	-11.76%
SMA50	-22.86%
SMA200	-31.38%
Trades

Shs Outstand	178.05M
Shs Float	144.92M
Short Float	25.27%
Short Ratio	6.14
Short Interest	36.62M
52W High	76.80 -50.13%
52W Low	37.57 1.94%
Volatility	4.16% 4.44%
ATR (14)	2.22
RSI (14)	30.07
Beta	2.05
Rel Volume	0.55
Avg Volume	5.96M
Volume	3,300,742

Perf Week	-4.66%
Perf Month	-22.31%
Perf Quarter	-11.20%
Perf Half Y	-36.93%
Perf YTD	-24.19%
Perf Year	-44.05%
Perf 3Y	130.03%
Perf 5Y	4.90%
Perf 10Y	-
Recom	1.28
Target Price	68.71
Prev Close	38.56
Price	38.30
Change %	-0.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-01-26	Initiated	Needham	Buy	$81
May-22-26	Initiated	Barclays	Overweight	$69
Apr-20-26	Initiated	Wedbush	Outperform	$90
Jan-13-26	Initiated	William Blair	Outperform
Dec-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$71
Nov-24-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$75
Nov-19-25	Initiated	Goldman	Buy	$77
Nov-14-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-10-25	Upgrade	Deutsche Bank	Hold → Buy	$71
Oct-09-25	Resumed	BMO Capital Markets	Market Perform	$76
Sep-23-25	Initiated	Daiwa Securities	Outperform	$80
Aug-01-25	Upgrade	Jefferies	Hold → Buy	$80
Jul-31-25	Resumed	Morgan Stanley	Equal-Weight	$65
Jul-07-25	Downgrade	Jefferies	Buy → Hold	$33
Jun-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$34
Sep-27-24	Reiterated	Robert W. Baird	Outperform	$20 → $25
Jul-15-24	Initiated	BMO Capital Markets	Market Perform	$16.50
Apr-23-24	Downgrade	JP Morgan	Overweight → Neutral	$20 → $16
Mar-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$26 → $15.50
Sep-06-23	Upgrade	Northland Capital	Market Perform → Outperform

Show Previous Ratings

Oct-23-26 01:28PM	Carrier Plans $600M Fort Worth Advanced Manufacturing Hub (CRE Daily)
Oct-14-26 09:25AM	Rare Earths Stock Extends Slide, Eyes 52-Week Low (Schaeffer's Research) -5.84%
Oct-08-26 05:00PM	OpenAIs Security Scare Points to 2 Cyber Stocks Worth Buying (InvestorPlace)
04:05PM	MP Materials Announces Date for Third Quarter 2026 Financial Results and Webcast (Business Wire)
Oct-07-26 05:53PM	Wolfspeed Stock Soars on Financing Deal with Pentagon (Barrons.com)
09:00AM	Loading…
Sep-29-26 09:00AM	Texas Emerges as a Hub for America's Rare Earth Supply Chain (PR Newswire)
Sep-22-26 09:00AM	Rare Earth Elements Market Projected to Reach $10.44 Billion by 2030 (PR Newswire)
Sep-21-26 09:34AM	Evolution Metals Just Joined the Indexes Behind $12.2 Trillion in Invested Assets (NASDAQ: EMAT) (FinanceWire) +5.80%
Sep-18-26 12:54PM	MP Materials Rises as Beijing Moves on Its Chinese Shareholder (GuruFocus.com)
05:30AM	Can Trump's Deals Survive the Next Congress? (Barrons.com)
Sep-17-26 09:09AM	The New Space Race Runs on Magnets. America Still Can't Make Enough (Nasdaq: EMAT) (FinanceWire)
Sep-14-26 04:26PM	Elmet Stock Surges on $450 Million Pentagon Deal for Tungsten (Barrons.com)
03:18AM	USAR, MP, UUUU, CRML Stocks Drop Overnight: Why China's Threat To Scrap Trump-Xi Summit Matters (Stocktwits)
Sep-11-26 08:30AM	The New Oil: Why Evolution Metals Might Be Positioned for the Magnet Squeeze (NASDAQ: EMAT) (FinanceWire)
Sep-10-26 07:00PM	Why The United States Belated Critical Minerals Gambit Wont Stop China (Oilprice.com) -5.49%
10:37AM	Loading…
10:37AM	Evolution Metals Projects $400 Million to $460 Million in 2027 Revenue as Magnet Output Scales (NASDAQ: EMAT) (FinanceWire)
Sep-09-26 09:00AM	Drones Are Now Mapping the Tungsten Ground America Walked Away From (PR Newswire)
08:30AM	Breaking the Dragon's Grip: How the U.S. Is Rebuilding Its Rare Earth Magnet Supply Chain (Nasdaq: EMAT) (FinanceWire)
01:45AM	The U.S.-China Worry List: Here's What Could Rattle the Fragile Detente (Barrons.com)
Sep-08-26 11:26AM	An Under the Radar Rare Earth Comment From Elon Musk Could Upend Another Industry (Barrons.com)
08:30AM	Defense Contractors Race to Audit & Replace Chinese Magnets; Evolution Metals Might Offer the Solution (FinanceWire)
Sep-04-26 03:49PM	Stocks Log Sluggish Start to September Amid Geopolitical Buzz (Schaeffer's Research)
10:00AM	MP Materials, Rare Earth Stocks Pop After China Curbs US Shipments (Schaeffer's Research)
08:20AM	MP, CRML, USAR Stocks In Focus: China Reportedly Blocks Some Rare Earth Shipments To US (Stocktwits)
Sep-03-26 09:29AM	Rare Earth Magnet Demand Is Accelerating. Evolution Metals Is Scaling Into the Opportunity (NASDAQ: EMAT) (FinanceWire)
Sep-02-26 04:05PM	MP Materials to Participate in Jefferies 2026 Global Industrials Conference (Business Wire)
02:45PM	15 Stocks to Watch With Short Squeeze Potential (Schaeffer's Research)
10:55AM	Military Drones Run on Chinese Magnets. Evolution Metals Is Building a Way Out (Nasdaq: EMAT) (FinanceWire)
09:14AM	USA Rare Earth Stock Stays Perfect With New Call to Buy (Barrons.com)
Sep-01-26 04:28PM	William Blair Says These Stocks Are Must-Own Picks (GuruFocus.com)
11:44AM	Loading…
Aug-26-26 11:44AM	Evolution Metals Is Making the Magnet Every Defense Prime Still Can't Source (NASDAQ: EMAT) (FinanceWire)
Aug-25-26 07:40PM	CRML Jumps, USAR And MP Advance As Rare-Earth Stocks Catch Government Tailwinds (Stocktwits)
12:13PM	The Rare Earth Mirage: The Midstream Bet Hiding in Plain Sight (NASDAQ: EMAT) (FinanceWire)
Aug-24-26 02:52PM	MP Materials Stock Moved On The Theme, Not On Mountain Pass (Trefis)
09:06AM	Evolution Metals to Join Russell Indexes as America's Rare Earth Magnet Buildout Hits Full Stride (EMAT) (FinanceWire)
Aug-21-26 09:00AM	With Physical AI On the Rise, The West Needs Magnets More than Ever (NASDAQ: EMAT) (FinanceWire) +9.10%
Aug-20-26 11:05AM	US Rare Earth Pure Play: Fireside with Tactical Resources CEO Ranjeet Sundher (IPO-Edge.com)
Aug-17-26 11:38AM	Trump Just Made Magnet Scrap a Defense Material. This Under-the-Radar Player Already Makes the Magnet (FinanceWire)
06:30AM	As Trump Cracks Down on Transshipment, Magnet Production Comes Into Focus (NASDAQ: EMAT) (FinanceWire)
Aug-14-26 03:13PM	MP Materials, USA Rare Earth Stock Rise Amid Trump Drone News; Energy Fuels Touted (Investor's Business Daily) +5.53%
12:35PM	Trump's New Drone Tariff Could Benefit These Under the Radar Stocks (NASDAQ: EMAT) (FinanceWire)
Aug-13-26 05:00PM	Why Are Four of Washington's Most Senior Defense Officials All Working for the Same Nasdaq Company? (FinanceWire)
06:55AM	How the U.S. Is Trying to Copy China's Supply Chain Playbook (Barrons.com)
Aug-07-26 04:05PM	MP Materials to Participate in Canaccord Genuitys 46th Annual Growth Conference (Business Wire) +7.62% +6.95%
03:39PM	Trump Touts $3 Billion in Minerals Projects to Counter China (Bloomberg)
04:27AM	MP Stock Heads For Best Week In 10 Months: CEO Says Demand Continues To 'Outpace Our Production Growth' (Stocktwits)
Aug-06-26 04:05PM	MP Materials Reports Second Quarter 2026 Results (Business Wire)
04:05PM	MP Earnings Show Chinese Rare-Earth Monopoly Is Fading (Barrons.com)
05:18AM	ConocoPhillips headlines Thursday's earnings (MarketWatch)
04:13AM	Stock Market Today: Dow eyes new record but S&P 500 steady and Nasdaq called lower as chips slip again after Sandisk dives on earnings and Korea slides; SpaceX lock-up expires. (MarketWatch)
Aug-05-26 08:30AM	The government owns some of the same stocks you do. Here's why that is risky. (MarketWatch)
08:08AM	MP Materials launches rare-earth magnet initiative (Manufacturing Dive)
Aug-03-26 07:00PM	China Is Getting More Anxious About Mythos Before Trump Meets Xi (Bloomberg) +5.97% +8.28%
Jul-31-26 04:44AM	MP, CRML, TMC, UAMY Stocks In Focus: Goldman Sachs Sees AI Driving A Global Mine-To-Magnet Investment Cycle (Stocktwits)
Jul-30-26 08:00AM	The United States is Investing In Its Domestic Rare Earth Industry (PR Newswire) +9.34%
Jul-29-26 08:00PM	Investors Are Racing to Find America's Next Rare Earth Winner (Oilprice.com) -7.70%
Jul-28-26 10:15AM	A Junior Just Pulled Rock Grading Double the Historical Numbers From a Nevada Tungsten District the U.S. Badly Needs (PR Newswire)
Jul-27-26 05:00PM	US Produces Just 300 Tons of Rare-Earth Magnets Against 48,000-Ton Demand (GuruFocus.com)
Jul-26-26 08:00PM	Chinas Rare Earth Strategy Is Forcing a U.S. Manufacturing Revolution (Oilprice.com)
11:49AM	Washington Has Quietly Built A Stock Portfolio That Nobody Can Size: Report (Stocktwits)
08:00AM	The U.S. government invested $27 billion in corporate stakes. Good luck finding them (Fortune)
Jul-23-26 02:58PM	Evolution Metals Is Executing on the Defense Supply Chain the White House is Pushing for (NASDAQ: EMAT) (FinanceWire)
07:53AM	This Boom Is for the AI-Anxious. 10 Ways to Cash In. (Barrons.com)
Jul-21-26 04:42AM	CRML, MP, UAMY, USAR, Stocks Gain Premarket: Retail Cheers Trump's Defense Critical Metals Supply Chain Push (Stocktwits)
Jul-20-26 07:47PM	Trump Signs Orders On Aluminum And Defense Supply Chains AA, KALU, CENX, MP Stocks In Focus (Stocktwits)
04:47PM	Trump Order to Secure Critical Minerals Supply Chain Underscores Risk to Defense Industry (Barrons.com)
04:29PM	Rare Earth Stocks Slide On Oversupply Fears (Investor's Business Daily)
Jul-16-26 04:05PM	MP Materials Announces Date for Second Quarter 2026 Financial Results and Webcast (Business Wire) -8.09%
Jul-13-26 05:43PM	HyProMag is the Magnet Opportunity Hiding in America's Scrap Heap (Exec Edge) -5.19%
11:39AM	Nova Minerals Advances U.S. Defense Supply Chain with Antimony Pilot Plant Buildout (IPO-Edge.com)
Jul-09-26 08:24AM	Rare Earth Talent Crunch Could Slow US Supply Chain Rebuild (GuruFocus.com)
06:00AM	Rare Earth Talent Scramble Lures 86-Year-Old From Retirement (Bloomberg)
Jul-07-26 08:00AM	The U.S. Is Increasing Efforts to Rebuild Its Rare Earth Supply Chain (PR Newswire)
Jul-06-26 09:00AM	The West Wants a Critical-Minerals Supply Chain Outside China. One Nasdaq Company Is Trying to Build a Piece of It in Greenland. (PR Newswire)
Jul-02-26 08:23AM	Evolution Metals Receives $12 Price Target and New 'Buy' Rating From Litchfield Hills Analyst (NASDAQ: EMAT) (FinanceWire)
12:42AM	St George Mining reports thickest Araxá intercept - ICYMI (Proactive)
Jun-28-26 11:00PM	The Cutthroat Battle to Become America's Rare-Earth Champion (The Wall Street Journal)
Jun-25-26 02:47PM	3 Reasons Contrarians Should Target MP Materials Stock (Schaeffer's Research)
Jun-22-26 01:37PM	MP Materials seen largely insulated after China export-control move (Investing.com)
10:55AM	A Greenland Rare Earth Story Is Accelerating as the West Races to Break China's Magnet Grip (PR Newswire)
09:46AM	MP Materials, USA Rare Earth Get China-Export-Ban Boost (Investor's Business Daily)
09:44AM	China targets US rare earth and other firms with export controls (Reuters Videos)
08:42AM	China Targets MP Materials, USA Rare Earth in Export Controls (GuruFocus.com)
08:39AM	China puts ten US firms on export controls blacklist (Investment Monitor)
01:09AM	MP, USAR Stocks In Focus: China Targets US Rare Earth Suppliers As Supply Chain Battle Intensifies (Stocktwits)
Jun-19-26 01:00AM	MP Materials' Litinsky Had a Mine and a Vision: to Secure a Rare Earths Supply in the U.S. (Barrons.com)
Jun-18-26 08:30AM	Here's why the richest person in Australia just bought a stake in SpaceX worth $1.4 billion (Moneywise)
Jun-16-26 04:05PM	MP Materials to Participate in the J.P. Morgan Natural Resources Conference (Business Wire) +6.64%
01:12PM	A Greenland Critical-Minerals Platform Is Taking Shape -- and It Just Pushed Into the Midstream Chokepoint (PR Newswire)
Jun-12-26 01:42PM	Energy Fuels Hits Uranium Output Target in 6 Months, Expands Into Rare Earths (IPO-Edge.com)
12:25PM	Stocks Are in the Black For the Week--How Did That Happen? (Schaeffer's Research)
Jun-09-26 08:00PM	America Just Added a Massive New Rare Earth Supply Source (Oilprice.com) -5.70%
Jun-08-26 12:49PM	MP Materials Stock's Bull Signal Has Never Been Wrong (Schaeffer's Research)
Jun-03-26 12:02PM	USA Rare Earth Hits Speed Bump As It Unlocks $1.6 Billion In U.S. Funding (Investor's Business Daily) -5.11%
Jun-02-26 12:23PM	Tracking Government Stakes and Stock Performance (Schaeffer's Research)
12:12PM	Rare Earth Stocks, Copper Plays Surging; FCX, MP Near Buy Points (Investor's Business Daily)
Jun-01-26 03:57PM	Rare Earth Stocks Are a Perfect Buy. So Are These 7. (Barrons.com) +7.09%
May-29-26 09:22AM	Inside The North Atlantic Critical Minerals Push: A $68 Billion Greenland Deposit Lands At The EU Raw Materials Summit (PR Newswire)
May-28-26 04:17PM	Drone Stocks Jump As Trump Administration Pursues Funding Deals (Investor's Business Daily)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rosenthal Michael Stuart	Chief Operating Officer	Jun 09 '26	Buy	54.30	10,000	543,000	136,622	Jun 10 09:01 AM
Litinsky James H.	Chairman and CEO	Jun 03 '26	Sale	69.14	185,167	12,801,855	11,620,798	Jun 05 08:05 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Jun 03 '26	Proposed Sale	68.53	250,000	17,132,500		Jun 03 04:36 PM
Litinsky James H.	Chairman and CEO	May 28 '26	Sale	65.87	234,651	15,455,481	11,855,965	May 29 08:59 PM
Litinsky James H.	Chairman and CEO	May 27 '26	Sale	65.37	115,349	7,540,632	12,090,616	May 29 08:59 PM
Litinsky James H.	Chairman and CEO	May 29 '26	Sale	64.58	50,000	3,229,112	11,805,965	May 29 08:59 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	May 29 '26	Proposed Sale	64.58	50,000	3,229,200		May 29 04:40 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	May 28 '26	Proposed Sale	66.10	200,000	13,220,325		May 28 04:38 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	May 27 '26	Proposed Sale	65.22	150,000	9,783,000		May 27 04:46 PM
Rosenthal Michael Stuart	Chief Operating Officer	May 20 '26	Buy	56.62	17,000	962,540	1,333,673	May 20 09:03 PM
Litinsky James H.	Chairman and CEO	May 13 '26	Sale	65.13	177,188	11,540,521	12,205,965	May 14 07:53 PM
Litinsky James H.	Chairman and CEO	May 12 '26	Sale	65.90	122,812	8,093,838	12,383,153	May 14 07:53 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	May 13 '26	Proposed Sale	65.12	150,000	9,767,299		May 13 04:51 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	May 12 '26	Proposed Sale	65.49	150,000	9,823,500		May 12 05:05 PM
Hoops Elliot Dean	General Counsel and Secretary	May 08 '26	Sale	75.00	6,958	521,850	54,095	May 08 09:24 PM
Corbett Ryan	Chief Financial Officer	May 08 '26	Sale	75.00	20,000	1,500,000	109,017	May 08 09:21 PM
Elliot Hoops	Officer	May 08 '26	Proposed Sale	75.00	6,958	521,850		May 08 04:18 PM
Corbett Ryan	Officer	May 08 '26	Proposed Sale	75.00	20,000	1,500,022		May 08 04:02 PM
Litinsky James H.	Chairman and CEO	Apr 20 '26	Sale	64.03	259,179	16,595,231	12,505,965	Apr 20 09:19 PM
Litinsky James H.	Chairman and CEO	Apr 17 '26	Sale	64.05	40,821	2,614,585	12,765,144	Apr 20 09:19 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Apr 20 '26	Proposed Sale	60.99	259,179	15,807,327		Apr 20 04:53 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Apr 17 '26	Proposed Sale	62.30	40,821	2,543,148		Apr 17 04:47 PM
Hoops Elliot Dean	General Counsel and Secretary	Mar 16 '26	Sale	60.01	13,914	834,979	61,053	Mar 17 08:20 PM
Corbett Ryan	Chief Financial Officer	Mar 17 '26	Sale	60.00	46,000	2,760,000	129,017	Mar 17 08:18 PM
Corbett Ryan	Officer	Mar 17 '26	Proposed Sale	60.00	46,000	2,760,055		Mar 17 04:31 PM
Elliot Hoops	Officer	Mar 16 '26	Proposed Sale	60.01	13,914	835,032		Mar 16 04:11 PM
Hoops Elliot Dean	General Counsel and Secretary	Jan 20 '26	Sale	68.21	7,823	533,607	74,967	Jan 22 07:48 PM
Elliot Hoops	officer	Jan 20 '26	Proposed Sale	68.21	7,823	533,569		Jan 20 04:36 PM
Litinsky James H.	Chairman and CEO	Jan 08 '26	Sale	64.17	272,600	17,492,742	12,805,965	Jan 09 09:48 PM
Litinsky James H.	Chairman and CEO	Jan 07 '26	Sale	64.01	27,400	1,753,874	13,078,565	Jan 09 09:48 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Jan 08 '26	Proposed Sale	62.50	272,600	17,037,500		Jan 08 04:25 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Jan 07 '26	Proposed Sale	59.82	27,400	1,639,068		Jan 07 04:57 PM
Corbett Ryan	Chief Financial Officer	Dec 09 '25	Sale	60.00	38,146	2,288,760	156,666	Dec 10 09:11 PM
Corbett Ryan	Officer	Dec 09 '25	Proposed Sale	60.00	38,146	2,288,760		Dec 09 04:14 PM
Litinsky James H.	Chairman and CEO	Dec 05 '25	Sale	62.94	385,000	24,232,308	13,105,965	Dec 05 09:45 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Dec 05 '25	Proposed Sale	62.94	385,000	24,231,092		Dec 05 04:29 PM
Litinsky James H.	Chairman and CEO	Nov 20 '25	Sale	63.86	248,411	15,864,583	13,369,665	Nov 20 09:40 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 20 '25	Proposed Sale	63.86	248,411	15,864,147		Nov 20 04:23 PM
Corbett Ryan	Chief Financial Officer	Nov 17 '25	Sale	57.72	20,000	1,154,400	194,812	Nov 19 09:21 PM
Corbett Ryan	Officer	Nov 17 '25	Proposed Sale	57.72	20,000	1,154,480		Nov 17 01:13 PM

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

Co-FounderMr. James Henry Litinsky

Co-Founder & COOMr. Michael Stuart Rosenthal

Chief Financial OfficerMr. Ryan S. Corbett

General Counsel & Corporate SecretaryMr. Elliot Dean Hoops

Chief Accounting Officer & Principal Accounting OfficerMr. David Gregory Infuso

ROIV

Roivant Sciences Ltd

MP

MP Materials Corp

Upgrade your Finviz experience